These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 2337738

  • 1. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC, LeMaistre CF, Zagars GK, Williams LA, Meneghetti CM, Luke DR, Dunphy FR, Spinolo JA, Jagannath S, Spitzer G.
    Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
    [Abstract] [Full Text] [Related]

  • 2. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD, Shore TB, Reece DE, Barnett MJ, Klingemann HG, Buskard NA, Phillips GL.
    Bone Marrow Transplant; 1988 Nov; 3(6):553-8. PubMed ID: 3063323
    [Abstract] [Full Text] [Related]

  • 3. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [Abstract] [Full Text] [Related]

  • 4. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R.
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [Abstract] [Full Text] [Related]

  • 5. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A, Greer JP, Stein RS, Goodman S, Brandt SA, Edwards JR, Wolff SN.
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
    Gondo H, Harada M, Taniguchi S, Akashi K, Hayashi S, Teshima T, Takamatsu Y, Eto T, Nagafuji K, Yamasaki K.
    Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM.
    N Engl J Med; 1993 Oct 21; 329(17):1225-30. PubMed ID: 8413388
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
    Aschan J, Ringdén O.
    Clin Transplant; 1994 Jun 21; 8(3 Pt 1):258-70. PubMed ID: 8061365
    [Abstract] [Full Text] [Related]

  • 9. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.
    Mrsić M, Labar B, Bogdanić V, Nemet D, Pavletić Z, Plavsić F, Dobrić I, Marusić M, Francetić I, Kastelan A.
    Bone Marrow Transplant; 1990 Aug 21; 6(2):137-41. PubMed ID: 2207450
    [Abstract] [Full Text] [Related]

  • 10. Continuous infusion cyclosporine and nifedipine to day +100 with short methotrexate and steroids as GVHD prophylaxis in unrelated donor transplants.
    Liesveld J, Duerst R, Rapoport A, Constine L, Abboud C, Packman C, Wedow L, Zwetsch L, McKenna B, Linder T, Silverman W, Swift S, Rowe J, DiPersio J.
    Bone Marrow Transplant; 1999 Sep 21; 24(5):511-6. PubMed ID: 10482935
    [Abstract] [Full Text] [Related]

  • 11. Prophylaxis of graft-versus-host disease with cyclosporine-prednisone is associated with increased risk of chronic graft-versus-host disease.
    Kumar S, Chen MG, Gastineau DA, Gertz MA, Inwards DJ, Lacy MQ, Tefferi A, Harmsen WS, Litzow MR.
    Bone Marrow Transplant; 2001 Jun 21; 27(11):1133-40. PubMed ID: 11551023
    [Abstract] [Full Text] [Related]

  • 12. Microangiopathy following allogeneic marrow transplantation. Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis.
    Kalhs P, Brugger S, Schwarzinger I, Greinix HT, Keil F, Kyrle PA, Knöbl P, Schneider B, Höcker P, Linkesch W.
    Transplantation; 1995 Nov 15; 60(9):949-57. PubMed ID: 7491699
    [Abstract] [Full Text] [Related]

  • 13. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D, Filipovich A, McGlave P, Ramsay N, Kersey J, Miller W, Blazar B.
    Bone Marrow Transplant; 1993 Nov 15; 12(5):531-6. PubMed ID: 8298565
    [Abstract] [Full Text] [Related]

  • 14. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM, Geller RB, Lin LB, Dix SP, Holland HK, Maurer D, O'Toole K, Keller J, Connaghan DG, Heffner LT, Hillyer CD, Rodey GE, Winton EF, Maher RM, Fitzsimmons WE, Wingard JR.
    Biol Blood Marrow Transplant; 1997 Apr 15; 3(1):25-33. PubMed ID: 9209738
    [Abstract] [Full Text] [Related]

  • 15. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL, Bloom EJ.
    Clin Pharm; 1993 Oct 15; 12(10):736-61. PubMed ID: 8258255
    [Abstract] [Full Text] [Related]

  • 16. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, Russell NH.
    Bone Marrow Transplant; 1998 Sep 15; 22(6):541-5. PubMed ID: 9758340
    [Abstract] [Full Text] [Related]

  • 17. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S, Bishop MR, Tarantolo S, Cowles MK, Reed E, Anderson JR, Vose JM, Bierman P, Armitage JO, Kessinger A.
    Exp Hematol; 1995 Dec 15; 23(14):1503-8. PubMed ID: 8542938
    [Abstract] [Full Text] [Related]

  • 18. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K, Downs K.
    Bone Marrow Transplant; 1995 Dec 15; 16(6):755-8. PubMed ID: 8750265
    [Abstract] [Full Text] [Related]

  • 19. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies.
    Uberti JP, Silver SM, Adams PT, Jacobson P, Scalzo A, Ratanatharathorn V.
    Bone Marrow Transplant; 1997 Jun 15; 19(12):1233-8. PubMed ID: 9208118
    [Abstract] [Full Text] [Related]

  • 20. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O, Labopin M, Gluckman E, Reiffers J, Vernant JP, Jouet JP, Harrousseau JL, Fiere D, Bacigalupo A, Frassoni F, Gorin NC.
    Bone Marrow Transplant; 1996 Nov 15; 18(5):921-9. PubMed ID: 8932846
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.